Remarks

The foregoing amendments to the specification are to insert the priority application information, for which this application claims benefit. The Abstract has been added as a separate sheet, and should be inserted following the claims in the specification.

The amendments to the claims re-define the scope of the invention. No new matter has been added.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (609) 627-8508

Date: April 28,2006

Joseph F. Majka Attorney for Applicants

Reg. No. 30,570